vida: extract claims from 2025-xx-one-big-beautiful-bill-medicaid-coverage-loss
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run

- Source: inbox/queue/2025-xx-one-big-beautiful-bill-medicaid-coverage-loss.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 5
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
This commit is contained in:
Teleo Agents 2026-05-10 08:33:03 +00:00
parent ca340cb750
commit f8eb476494
4 changed files with 25 additions and 2 deletions

View file

@ -102,3 +102,10 @@ The AI productivity concentration pattern mirrors the GLP-1 access inversion: AI
**Source:** National Law Review, FDA April 1 2026 clarification on compounded GLP-1 policy **Source:** National Law Review, FDA April 1 2026 clarification on compounded GLP-1 policy
FDA April 1, 2026 clarification establishes that 503A pharmacies retain a narrow safe harbor (4 or fewer prescriptions per month) for compounded semaglutide at $99/month, but this limit is architecturally designed to prevent population-scale access. The 503B outsourcing facility pathway is effectively closed (neither semaglutide nor tirzepatide appear on FDA's 503B bulks list or drug shortage list). Federal courts have blocked some 503B enforcement through injunctions, creating a legally contested patchwork. The compounding channel survived two grace period deadlines (April/May 2025) and remains operational in April 2026, but FDA enforcement is systematically closing it through regulatory mechanics rather than outright prohibition. This makes 2031-2033 patent expiry the next realistic systemic access event for population-scale affordable GLP-1 access in the US. FDA April 1, 2026 clarification establishes that 503A pharmacies retain a narrow safe harbor (4 or fewer prescriptions per month) for compounded semaglutide at $99/month, but this limit is architecturally designed to prevent population-scale access. The 503B outsourcing facility pathway is effectively closed (neither semaglutide nor tirzepatide appear on FDA's 503B bulks list or drug shortage list). Federal courts have blocked some 503B enforcement through injunctions, creating a legally contested patchwork. The compounding channel survived two grace period deadlines (April/May 2025) and remains operational in April 2026, but FDA enforcement is systematically closing it through regulatory mechanics rather than outright prohibition. This makes 2031-2033 patent expiry the next realistic systemic access event for population-scale affordable GLP-1 access in the US.
## Extending Evidence
**Source:** CBO estimates, One Big Beautiful Bill Act 2025
The One Big Beautiful Bill Act creates a double coverage compression: Medicaid work requirements eliminate coverage for 11.8M (disproportionately affecting populations with highest obesity/CVD burden), while enhanced APTC expiration affects those above Medicaid income threshold. This systematically removes coverage from the populations with highest clinical need for GLP-1 therapy, amplifying the existing access inversion.

View file

@ -33,4 +33,10 @@ CBO estimates 5.2M Medicaid coverage loss from OBBBA work requirements by 2034,
# Medicaid work requirements cause coverage loss through procedural churn not employment screening because 5.3 million projected uninsured exceeds the population of able-bodied unemployed adults # Medicaid work requirements cause coverage loss through procedural churn not employment screening because 5.3 million projected uninsured exceeds the population of able-bodied unemployed adults
The CBO projects 5.3 million Americans will lose Medicaid coverage by 2034 due to work requirements — the single largest driver among all OBBBA provisions. This number is structurally revealing: it exceeds the population of able-bodied unemployed Medicaid adults, meaning the coverage loss cannot be primarily from screening out the unemployed. Instead, the mechanism is procedural churn: monthly reporting requirements (80 hrs/month documentation) create administrative barriers that cause eligible working adults to lose coverage through paperwork failures, not employment status. This is confirmed by the timeline: 1.3M uninsured in 2026 → 5.2M in 2027 shows rapid escalation inconsistent with gradual employment screening but consistent with cumulative procedural attrition. The work requirement functions as a coverage reduction mechanism disguised as an employment incentive. The CBO projects 5.3 million Americans will lose Medicaid coverage by 2034 due to work requirements — the single largest driver among all OBBBA provisions. This number is structurally revealing: it exceeds the population of able-bodied unemployed Medicaid adults, meaning the coverage loss cannot be primarily from screening out the unemployed. Instead, the mechanism is procedural churn: monthly reporting requirements (80 hrs/month documentation) create administrative barriers that cause eligible working adults to lose coverage through paperwork failures, not employment status. This is confirmed by the timeline: 1.3M uninsured in 2026 → 5.2M in 2027 shows rapid escalation inconsistent with gradual employment screening but consistent with cumulative procedural attrition. The work requirement functions as a coverage reduction mechanism disguised as an employment incentive.
## Supporting Evidence
**Source:** CBO/CBPP analysis, One Big Beautiful Bill Act 2025
CBO estimates work requirements alone will cause 5.2 million Medicaid coverage reduction by 2034, with 4.8 million becoming newly uninsured. CBPP estimates 9.9-14.9 million at risk. Prior state work requirement experiments led enrollees to take on more medical debt, delay care, and delay medications—confirming that coverage loss is administrative churning, not behavioral employment response.

View file

@ -25,3 +25,10 @@ The OBBBA introduces semi-annual eligibility redeterminations (starting October
**Source:** KFF Medicaid GLP-1 coverage analysis, January 2026 **Source:** KFF Medicaid GLP-1 coverage analysis, January 2026
State Medicaid coverage instability now extends beyond enrollment churn to coverage policy reversal. Four states eliminated GLP-1 obesity coverage in 2025-2026, meaning patients who began treatment under coverage may lose access mid-therapy. This policy-level instability compounds enrollment churn, further undermining the multi-year attribution required for prevention ROI in value-based care models. State Medicaid coverage instability now extends beyond enrollment churn to coverage policy reversal. Four states eliminated GLP-1 obesity coverage in 2025-2026, meaning patients who began treatment under coverage may lose access mid-therapy. This policy-level instability compounds enrollment churn, further undermining the multi-year attribution required for prevention ROI in value-based care models.
## Supporting Evidence
**Source:** One Big Beautiful Bill Act provisions, CBO 2025
The One Big Beautiful Bill Act mandates Medicaid eligibility redeterminations at least once every 6 months (previously annual), starting 2026. This accelerated churning, combined with work requirements and enhanced FMAP sunset, creates systematic enrollment instability. CBO projects 11.8M losing Medicaid coverage by 2034, destroying the multi-year patient attribution required for prevention-first VBC models to realize ROI.

View file

@ -7,10 +7,13 @@ date: 2025-01-01
domain: health domain: health
secondary_domains: [] secondary_domains: []
format: policy-analysis format: policy-analysis
status: unprocessed status: processed
processed_by: vida
processed_date: 2026-05-10
priority: high priority: high
tags: [Medicaid, coverage-loss, One-Big-Beautiful-Bill, work-requirements, CBO, health-access, VBC, uninsured, policy, DOGE] tags: [Medicaid, coverage-loss, One-Big-Beautiful-Bill, work-requirements, CBO, health-access, VBC, uninsured, policy, DOGE]
intake_tier: research-task intake_tier: research-task
extraction_model: "anthropic/claude-sonnet-4.5"
--- ---
## Content ## Content